Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | MME | P08473 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ACE | P12821 | 6/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL598434 | 1.00 | FOLH1 (0.50) | FOLH1NAALAD2SLC7A5CA1CA2 | |
| SCHEMBL972349 | 0.87 | MME (0.50) | NAALAD2MMEL3MBTL1 | |
| SCHEMBL972348 | 0.87 | MME (0.50) | NAALAD2MMEL3MBTL1 | |
| SCHEMBL30063731 | 0.86 | KMT2A (0.50) | CA2KMT2ASLC6A4 | |
| SCHEMBL30063692 | 0.86 | ALDH1A1 (0.50) | FOLH1CA2MMEKMT2AL3MBTL1 | |
| SCHEMBL30063819 | 0.86 | TDP1 (0.48) | FOLH1MMEKMT2AL3MBTL1ACE | |
| Hydrochloric Acid SCHEMBL8133191 | 0.86 | MME (0.49) | NAALAD2MMEL3MBTL1 | |
| Hydrochloric Acid SCHEMBL8133188 | 0.86 | MME (0.49) | NAALAD2MMEL3MBTL1 | |
| SCHEMBL27865676 | 0.85 | ESR1 (0.54) | KMT2A | |
| Fluoride SCHEMBL29086588 | 0.84 | MME (0.48) | NAALAD2MMEL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109069664-A | anti-CD 74 antibody conjugates, compositions comprising anti-CD 74 antibody conjugates, and methods of use of anti-CD 74 antibody conjugates | 苏特罗生物制药公司 | 2018-12-21 | — | — | CN | claimed |
| CN-101913973-A | Preparation and use of alkylating agents | QUEENS MEDICAL CT | 2010-12-15 | — | — | CN | claimed |
| CN-1886362-A | Preparation and use of alkylating agents | QUEENS MEDICAL CT (US) | 2006-12-27 | — | — | CN | claimed |
| EP-1490483-A2 | IN VIVO INCORPORATION OF UNNATURAL AMINO ACIDS | The Scripps Research Institute (US) | 2004-12-29 | — | — | EP | claimed |
| US-20030082575-A1 | Translation system for use in the generation of protein containing adjusted amino acid sequences | THE SCRIPPS RESEARCH INSTITUTE (US) | 2003-05-01 | — | — | US | claimed |
| WO-2002085923-A2 | IN VIVO INCORPORATION OF UNNATURAL AMINO ACIDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2002-10-31 | — | — | WO | claimed |
| CN-87102304-A | Pharmaceutical preparation containing compounds with antidementia effect and its application in preventing and treating cognitive dysfunction | — | 1987-12-30 | — | — | CN | claimed |
| CN-115717130-B | Aminoacyl-tRNA synthase mutants and methods of making alkenyl tyrosyl-tRNAs | 凯莱英医药集团（天津）股份有限公司 | 2024-10-15 | — | — | CN | disclosed |
| US-12084663-B2 | Incorporation of unnatural amino acids into proteins using base editing | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-09-10 | — | — | US | disclosed |
| WO-2024077277-A1 | DRUG LINKERS AND ANTIBODY CONJUGATES THEREOF | AMBRX, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| EP-4308170-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | Seagen Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-115717130-A | aminoacyl-tRNA (tRNA) synthase mutant and preparation method of alkenyltyrosyl-tRNA | 凯莱英医药集团（天津）股份有限公司 | 2023-02-28 | — | — | CN | disclosed |
| US-11591366-B2 | Macrocyclic compounds and methods of preventing or treating pain | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2023-02-28 | — | — | US | disclosed |
| EP-0770132-A1 | STREPTOGRAMINES AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS | Aventis Pharma S.A. (FR) | 1997-05-02 | — | — | EP | disclosed |
| CN-1031267-C | Compounds for anti-dementia medicine and its usage | HOECHST AG (DE) | 1996-03-13 | — | — | CN | disclosed |
| WO-1996001901-A1 | STREPTOGRAMINES AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS | RHONE-POULENC RORER S.A. (FR) | 1996-01-25 | — | — | WO | disclosed |
| EP-0597838-A1 | VACCINE COMPOSITIONS | NORTH AMERICAN VACCINE, INC. (CA) | 1994-05-25 | — | — | EP | disclosed |
| WO-1991016926-A1 | VACCINE COMPOSITIONS | NORTH AMERICAN VACCINE, INC. (CA) | 1991-11-14 | — | — | WO | disclosed |
| EP-0352000-A2 | Retroviral protease binding peptides | SMITHKLINE BEECHAM CORPORATION (US) | 1990-01-24 | — | — | EP | disclosed |
| CN-87102304-A | Pharmaceutical preparation containing compounds with antidementia effect and its application in preventing and treating cognitive dysfunction | — | 1987-12-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591366-B2 | Macrocyclic compounds and methods of preventing or treating pain | COX15, ACHE, TRPV1 | FOLH1 1583/4885NAALAD2 1956/4885SLC7A5 3660/4885 |
| US-12084663-B2 | Incorporation of unnatural amino acids into proteins using base editing | UPF1, NPEPPS, NUDT21 | FOLH1 1310/4885NAALAD2 666/4885SLC7A5 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.